Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients
Abstract Background The chemokine receptor CXCR4 is frequently overexpressed and associated with adverse prognosis in most hematopoietic malignancies and solid cancers. Recently, CXCR4 molecular imaging using the CXCR4-specific positron emission tomography (PET) tracer Pentixafor ([68Ga]Pentixafor)...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2021-08-01
|
| Series: | EJNMMI Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13550-021-00822-6 |
| _version_ | 1818902356135247872 |
|---|---|
| author | Richard Lewis Stefan Habringer Malte Kircher Maike Hefter Caroline Anna Peuker Rudolf Werner Valëza Ademaj-Kospiri Alexander Gäble Wolfgang Weber Hans-Jürgen Wester Andreas Buck Peter Herhaus Constantin Lapa Ulrich Keller |
| author_facet | Richard Lewis Stefan Habringer Malte Kircher Maike Hefter Caroline Anna Peuker Rudolf Werner Valëza Ademaj-Kospiri Alexander Gäble Wolfgang Weber Hans-Jürgen Wester Andreas Buck Peter Herhaus Constantin Lapa Ulrich Keller |
| author_sort | Richard Lewis |
| collection | DOAJ |
| description | Abstract Background The chemokine receptor CXCR4 is frequently overexpressed and associated with adverse prognosis in most hematopoietic malignancies and solid cancers. Recently, CXCR4 molecular imaging using the CXCR4-specific positron emission tomography (PET) tracer Pentixafor ([68Ga]Pentixafor) has become a well-established method to non-invasively measure CXCR4 expression in vivo. In previous Pentixafor imaging studies, highly variable CXCR4 tracer uptake to the spleen was observed. Results We investigated the hypothesis that enhanced spleen [68Ga]Pentixafor uptake and thus CXCR4 expression in patients with solid tumors would indicate an activated spleen state and/or an association with clinical and prognostic features and survival parameters. In this retrospective study, [68Ga]Pentixafor-PET images and patient records of 145 solid tumor patients representing 27 cancer entities were investigated for an association of spleen [68Ga]Pentixafor uptake and clinical characteristics and outcome. Based on this assessment, we did not observe differences in clinical outcomes, measured by progression-free survival, overall survival and remission status neither within the entire cohort nor within subgroups of adrenal cancer, desmoplastic small round cell tumor, neuroendocrine tumors, non-small cell lung cancer, small cell lung cancer and pancreatic adenocarcinoma patients. No tumor entity showed especially high levels of spleen [68Ga]Pentixafor uptake compared to others or a control cohort. However, when investigating laboratory parameters, there was a positive correlation of high spleen [68Ga]Pentixafor uptake with leukocyte and/or platelet counts in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer. Conclusion Spleen [68Ga]Pentixafor uptake was not associated with stage of disease and clinical outcomes in solid tumor patients. We identified positively associated platelet and/or leukocyte counts with spleen [68Ga]Pentixafor uptake in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer, suggesting that splenic CXCR4 expression could possibly play a role in systemic immunity/inflammation in some types of solid tumors or a subgroup of patients within solid tumor entities. |
| first_indexed | 2024-12-19T20:34:21Z |
| format | Article |
| id | doaj.art-fae0cd3353e3432086d22231594a6061 |
| institution | Directory Open Access Journal |
| issn | 2191-219X |
| language | English |
| last_indexed | 2024-12-19T20:34:21Z |
| publishDate | 2021-08-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | EJNMMI Research |
| spelling | doaj.art-fae0cd3353e3432086d22231594a60612022-12-21T20:06:36ZengSpringerOpenEJNMMI Research2191-219X2021-08-0111111010.1186/s13550-021-00822-6Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patientsRichard Lewis0Stefan Habringer1Malte Kircher2Maike Hefter3Caroline Anna Peuker4Rudolf Werner5Valëza Ademaj-Kospiri6Alexander Gäble7Wolfgang Weber8Hans-Jürgen Wester9Andreas Buck10Peter Herhaus11Constantin Lapa12Ulrich Keller13Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu BerlinDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu BerlinNuclear Medicine, Medical Faculty, University of AugsburgClinic and Policlinic for Internal Medicine III, School of Medicine, Technical University of MunichDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu BerlinDepartment of Nuclear Medicine, University of WürzburgClinic for Nuclear Medicine, School of Medicine, Technical University of MunichNuclear Medicine, Medical Faculty, University of AugsburgClinic for Nuclear Medicine, School of Medicine, Technical University of MunichChair of Pharmaceutical Chemistry, Technical University of MunichDepartment of Nuclear Medicine, University of WürzburgClinic and Policlinic for Internal Medicine III, School of Medicine, Technical University of MunichNuclear Medicine, Medical Faculty, University of AugsburgDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu BerlinAbstract Background The chemokine receptor CXCR4 is frequently overexpressed and associated with adverse prognosis in most hematopoietic malignancies and solid cancers. Recently, CXCR4 molecular imaging using the CXCR4-specific positron emission tomography (PET) tracer Pentixafor ([68Ga]Pentixafor) has become a well-established method to non-invasively measure CXCR4 expression in vivo. In previous Pentixafor imaging studies, highly variable CXCR4 tracer uptake to the spleen was observed. Results We investigated the hypothesis that enhanced spleen [68Ga]Pentixafor uptake and thus CXCR4 expression in patients with solid tumors would indicate an activated spleen state and/or an association with clinical and prognostic features and survival parameters. In this retrospective study, [68Ga]Pentixafor-PET images and patient records of 145 solid tumor patients representing 27 cancer entities were investigated for an association of spleen [68Ga]Pentixafor uptake and clinical characteristics and outcome. Based on this assessment, we did not observe differences in clinical outcomes, measured by progression-free survival, overall survival and remission status neither within the entire cohort nor within subgroups of adrenal cancer, desmoplastic small round cell tumor, neuroendocrine tumors, non-small cell lung cancer, small cell lung cancer and pancreatic adenocarcinoma patients. No tumor entity showed especially high levels of spleen [68Ga]Pentixafor uptake compared to others or a control cohort. However, when investigating laboratory parameters, there was a positive correlation of high spleen [68Ga]Pentixafor uptake with leukocyte and/or platelet counts in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer. Conclusion Spleen [68Ga]Pentixafor uptake was not associated with stage of disease and clinical outcomes in solid tumor patients. We identified positively associated platelet and/or leukocyte counts with spleen [68Ga]Pentixafor uptake in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer, suggesting that splenic CXCR4 expression could possibly play a role in systemic immunity/inflammation in some types of solid tumors or a subgroup of patients within solid tumor entities.https://doi.org/10.1186/s13550-021-00822-6Solid tumorsClinical studiesRetrospective studiesMolecular imagingPETCXCR4 |
| spellingShingle | Richard Lewis Stefan Habringer Malte Kircher Maike Hefter Caroline Anna Peuker Rudolf Werner Valëza Ademaj-Kospiri Alexander Gäble Wolfgang Weber Hans-Jürgen Wester Andreas Buck Peter Herhaus Constantin Lapa Ulrich Keller Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients EJNMMI Research Solid tumors Clinical studies Retrospective studies Molecular imaging PET CXCR4 |
| title | Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients |
| title_full | Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients |
| title_fullStr | Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients |
| title_full_unstemmed | Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients |
| title_short | Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients |
| title_sort | investigation of spleen cxcr4 expression by 68ga pentixafor pet in a cohort of 145 solid cancer patients |
| topic | Solid tumors Clinical studies Retrospective studies Molecular imaging PET CXCR4 |
| url | https://doi.org/10.1186/s13550-021-00822-6 |
| work_keys_str_mv | AT richardlewis investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT stefanhabringer investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT maltekircher investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT maikehefter investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT carolineannapeuker investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT rudolfwerner investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT valezaademajkospiri investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT alexandergable investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT wolfgangweber investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT hansjurgenwester investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT andreasbuck investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT peterherhaus investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT constantinlapa investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients AT ulrichkeller investigationofspleencxcr4expressionby68gapentixaforpetinacohortof145solidcancerpatients |